These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25409376)

  • 1. ROS1--targeting the one percent in lung cancer.
    Gold KA
    N Engl J Med; 2014 Nov; 371(21):2030-1. PubMed ID: 25409376
    [No Abstract]   [Full Text] [Related]  

  • 2. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
    Arnaoutakis K
    N Engl J Med; 2015 Feb; 372(7):683. PubMed ID: 25671265
    [No Abstract]   [Full Text] [Related]  

  • 3. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
    Shaw AT; Solomon BJ
    N Engl J Med; 2015 Feb; 372(7):683-4. PubMed ID: 25671264
    [No Abstract]   [Full Text] [Related]  

  • 4. Lung cancer: alternative rearrangements--targeting ROS1 in NSCLC.
    Killock D
    Nat Rev Clin Oncol; 2014 Nov; 11(11):624. PubMed ID: 25311353
    [No Abstract]   [Full Text] [Related]  

  • 5. Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients.
    Juan O; Popat S
    Lung Cancer; 2017 Feb; 104():131-133. PubMed ID: 27863911
    [No Abstract]   [Full Text] [Related]  

  • 6. Validating ROS1 rearrangements as a therapeutic target in non-small-cell lung cancer.
    Solomon B
    J Clin Oncol; 2015 Mar; 33(9):972-4. PubMed ID: 25667277
    [No Abstract]   [Full Text] [Related]  

  • 7. [Crizotinib for ROS1-rearranged non-small cell lung cancer patients].
    Domblides C; Antoine M; Lavole A; Cadranel J; Wislez M
    Bull Cancer; 2017 Apr; 104(4):303-310. PubMed ID: 28237354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crizotinib in ROS1 rearranged non-small cell lung cancer (NSCLC), from response to resistance.
    Zhong E; Huang H
    BMJ Case Rep; 2016 Oct; 2016():. PubMed ID: 27797842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A new target in non-small cell lung cancer: ROS1 fusion gene].
    Cai WJ; Su B
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):1-4. PubMed ID: 23648291
    [No Abstract]   [Full Text] [Related]  

  • 10. Response to crizotinib observed in metastatic mediastinum lymph node from a non-small cell lung cancer patient harboring EZR-ROS1 fusion.
    Li H; Pan Y; Wang R; Li Y; Sun Y; Chen H
    J Cancer Res Clin Oncol; 2015 Jan; 141(1):185-7. PubMed ID: 25230898
    [No Abstract]   [Full Text] [Related]  

  • 11. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
    Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
    Mazières J; Zalcman G; Crinò L; Biondani P; Barlesi F; Filleron T; Dingemans AM; Léna H; Monnet I; Rothschild SI; Cappuzzo F; Besse B; Thiberville L; Rouvière D; Dziadziuszko R; Smit EF; Wolf J; Spirig C; Pecuchet N; Leenders F; Heuckmann JM; Diebold J; Milia JD; Thomas RK; Gautschi O
    J Clin Oncol; 2015 Mar; 33(9):992-9. PubMed ID: 25667280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired resistance to crizotinib from a mutation in CD74-ROS1.
    Awad MM; Engelman JA; Shaw AT
    N Engl J Med; 2013 Sep; 369(12):1173. PubMed ID: 24047072
    [No Abstract]   [Full Text] [Related]  

  • 14. An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.
    Dziadziuszko R; Le AT; Wrona A; Jassem J; Camidge DR; Varella-Garcia M; Aisner DL; Doebele RC
    J Thorac Oncol; 2016 Aug; 11(8):1273-1281. PubMed ID: 27068398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ROS1 [corrected].
    Pal P; Khan Z
    J Clin Pathol; 2017 Dec; 70(12):1001-1009. PubMed ID: 28903995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Successful Therapy of Czech Patients with ROS1 Translocation by Crizotinib].
    Svaton M; Pešek M
    Klin Onkol; 2016; 29(1):63-5. PubMed ID: 26879065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired resistance to crizotinib from a mutation in CD74-ROS1.
    Gerlinger M; Norton L; Swanton C
    N Engl J Med; 2013 Sep; 369(12):1172-3. PubMed ID: 24047073
    [No Abstract]   [Full Text] [Related]  

  • 18. Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.
    Lu S; Azada MC; Ou SH
    Lung Cancer; 2015 Feb; 87(2):207-9. PubMed ID: 25558789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ROS1 Rearrangement in a Case of Classic Biphasic Pulmonary Blastoma.
    Jenkins TM; Morrissette JJD; Kucharczuk JC; Deshpande CG
    Int J Surg Pathol; 2018 Jun; 26(4):360-363. PubMed ID: 29295663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of ROS1 rearrangements detection in advanced squamous cell carcinomas.
    Gibelin C; Avrillon V; De La Fouchardiere A; Mc Leer-Florin A; Lantuejoul S; Fayette J
    Lung Cancer; 2016 Dec; 102():42-43. PubMed ID: 27987587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.